| Business Summary | | Orphan
Medical,
Inc.
acquires,
develops
and
markets
products
of
high
medical
value
for
patients
within
selected
strategic
therapeutic
market
segments
(STMS).
The
Company
currently
concentrates
on
drugs
with
high
medical
value
that
may
be
marketed
within
three
selected
STMS:
Antidotes,
Oncology
Support,
and
Sleep
Disorders.
Antizol
and
Busulfex
are
commercially
available
and
are
the
Company's
lead
products
in
its
Antidote
and
Oncology
Support
STMS,
respectively.
Xyrem
is
an
investigational
drug
and
is
expected
to
be
the
Company's
lead
product
in
its
Sleep
Disorders
STMS.
In
addition,
the
Company
manufactures
and
distributes
Cystadane
and
Sucraid
that
treat
two
rare
congenital
diseases.
Antizol-Vet
is
marketed
through
separate
channels
to
the
veterinary
community
although
these
products
do
not
fall
into
any
of
the
three
selected
STMS. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Orphan
Medical
acquires,
develops
and
markets
products
of
high
medical
value
for
patients
within
selected
strategic
therapeutic
market
segments.
For
the
six
months
ended
6/30/01,
revenues
decreased
17%
to
$4.8
million.
Net
loss
applicable
to
Common
increased
52%
to
$3.5
million.
Revenues
reflect
decreased
sales
of
Antizol.
Net
loss
reflects
increased
S/G/A
expenses
and
a
decreased
gross
profit
due
to
a
change
in
product
mix. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Bullion, 49 Chairman,
CEO, Sec. | $181K | Timothy McGrath, 36 CFO,
VP | 183K | William Houghton, M.D., 58 COO | 226K | Patti Engel, 40 VP
of Marketing and Sales | 232K | Dayton Reardan, Ph.D., 45 VP
of Regulatory Affairs | 181K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|